Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

Diffuse Diabetic Macular Edema Clinical Trial

Official title:
Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)

Status Terminated

Clinical Trial Summary

To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00571142
Study type	Interventional
Source	Asociación para Evitar la Ceguera en México
Contact
Status	Terminated
Phase	Phase 3
Start date	November 2007
Completion date	February 2008

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00567372` - POSTERIOR SUB-TENON'S Avastin	Phase 4
Recruiting	`NCT00999791` - Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema	Phase 1
Withdrawn	`NCT00600301` - Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study	Phase 3
Completed	`NCT00886808` - Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema	Phase 1
Recruiting	`NCT01218750` - Triple Therapy for Diffuse Diabetic Macular Edema	N/A